Healthcare

Imugene Secures Option Underwriting Agreement with Bell Potter to Ra...

NSW-headquartered clinical stage immuno-oncology firm, Imugene Limited (ASX:IMU) has secured an underwriting agreement with Bell Potter Securities Lim...

SUDA Secures Australian Patent Office’s Approval on Anagrelide Cance...

Summary SUDA’s share price soared by ~12% on securing approval for anagrelide cancer patent in Australia. With the Australian Patent Office...

Imugene Attains First US Ethics Approval from WIRB to Begin PD1-Vaxx...

Australia-based immuno-oncology company Imugene Limited (ASX:IMU) has recently marked a great leap forward by attaining the first ethics approval in t...

ASX Share Price to Watch - Telix Pharmaceuticals; announces prostate...

Summary ASX-listed biopharmaceutical player Telix Pharmaceuticals announced a strategic collaboration agreement with Palo Alto-based Varian Medical...

Noxopharm to Commence Veyonda^®’s Clinical Trial in COVID-...

Australian biotech, Noxopharm Limited (ASX:NOX) has announced an important milestone with formal approval for immediate initiation of Veyonda®&rsq...

Imugene’s FY20 Report Card Out, Outlines Notable Operational Achieve...

In a latest update, the biotech company Imugene Limited (ASX:IMU) has published its Annual Report for the year ended 30th June 2020 on the ASX. The fi...

Scan Through SUDA’s Key Operational Achievements in FY 2019-2020

Summary SUDA reported key operational achievements for FY 2019-2020. The Company finalised a key agreement with Cann Pharma Australia during the y...

Australian Cannabis Sector’s Growth Continues; Lens on Althea and MG...

The Australian cannabis industry is growing continuously dodging the impact of COVID-19 pandemic. The cannabis industry in Australia will be able to e...

ASX 200 Pharma Player Set to Race into the Mighty US Market, With a...

A recent ASX200 entrant midcap pharma company, aggressively cutting costs as it prepares to take its drug RYONCIL™ into the mighty US healthcare...

PTX Solidifies Balance Sheet Further: Announces A$7 million Placemen...

On 26 August 2020, Prescient Therapeutics Limited (ASX:PTX) announced that it has received firm commitments to raise A$7,046,084 (before costs) by way...

Imugene Receives Third Ethics Approval for PD1-Vaxx’s Phase 1 Trial...

The stock of Australian clinical-stage immuno-oncology company, Imugene Limited (ASX:IMU) traded ~1.8 per cent higher on 21st August 2020 following th...

Needle on CardieX Limited: What's Driving the Impressive Stock Perfo...

Global health technology company, CardieX Limited (ASX:CDX) has experienced a stupendous price rally with a six-month investor return of more than 107...

E-health Services - the Apparent Next Step Amid Digital Boom and Pan...

Summary Australian government intends to develop a national approach for digital health; however, challenges are hampering the pace of development....

Is CSL share price still a buy this year?

Summary Biotech player CSL Limited announced its FY20 results with an impressive growth of 17% and 9% in net profit after tax and revenue, respecti...

Latest updates in healthcare space: Lens on EMD and AT1

Since the onset of a pandemic, the health system of Australia has experienced both challenges and opportunities as a result of COVID-19. Many companie...

COVID-19: A Catastrophe For Most But A Boon For Some; Biotech Player...

Summary Covid-19 pandemic appears to boost the market opportunity for biotech companies, mainly involved in the development of COVID-19 related tes...

Only ASX-listed Healthcare Company Developing CAR-T Programs- PTX Co...

Summary Prescient collaborating with the world-class cell therapy institute Peter MacCallum Cancer Centre to develop innovative cell therapy techno...

Why Healthcare Stocks Seem to be Losing Some Fizz - A Glance at Phar...

Healthcare sector of Australia offers several services and products through its constituent companies, such as healthcare services providers, medical...

Prescient Therapeutics’ PTX100 Phase 1b Basket Study Progressing Wel...

Summary After demonstrating the safety at a dose of 1,000 mg/m2, Phase 1b study of PTX-100 will proceed to the increased dose of 2,000 mg/m2. Two...

Investors Smile with ASX-listed 1300 Smiles’ Stock Price Momentum

The growing number of COVID-19 cases have led to several businesses going bankrupt with forced to ask their employees to work from home amid the pande...